PD-1/PD-L1 inhibitors can specifically bind to PD-L1 on tumor cells to inhibit its expression, thereby restoring recognition of tumor cells by functionally suppressed T cells and achieving anti-cancer effects. This evidence concerns the gene PDCD1 and cancer.